SMARCC2 and lung adenocarcinoma: Taken together, further research is required on SMARCC1, SMARCC2, and SMARCA5, together with TOP1, as predictive biomarkers of resistance to geldanamycin derivatives as HSP90 inhibitors in lung adenocarcinoma.